| Subcribe via RSS



Inotek Pharmaceuticals Closes $18 Million Preferred Stock Financing

June 10th, 2010

Proceeds from the financing will be used to advance Inotek’s novel eye-drop INO-8875 through multiple-dose Phase 2 clinical trials in glaucoma.

Original post by Freshnews


(click on the author/publication link above to see full post)
This entry was posted on Thursday, June 10th, 2010 at 3:51 pm. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

«
»